Home/ News/ Detail Nerviano Medical Sciences announces collaboration and license agreement with Merck to discover small molecule inhibitors of certain anticancer targets Share Print 11 July 2018 - Nerviano Medical Sciences announces an agreement with Merck, a leading science and technology company, under which the two companies will collaborate on the discovery of small molecule inhibitors for development as anticancer agents. Nerviano Medical Sciences, pharmaceutical R&D facility, one of the leading oncology-focused, integrated discovery and development companies in Europe, announces an agreement with Merck, a leading science and technology company, under which the two companies will collaborate on the discovery of small molecule inhibitors for development as anticancer agents. Under the terms of the agreement, Nerviano Medical Sciences grants Merck an exclusive right to conduct joint research and to develop, manufacture and commercialize inhibitors of certain molecular targets in the area of DNA damage repair. More info: https://www.nervianoms.com/en/news-media-en/press-release/media-releases-news-2018/nerviano-medical-sciences-announces-collaboration-and-license-agreement-with-merck-to-discover-small-molecule-inhibitors-of-certain-anticancer-targets/